KOREA WHO
-
-
-
CEO & President of SK Bioscience Co Ltd.
Ahn Jae-yong
Vaccine Business Thrives on Failure; Emphasis on Engaging Work Environment
-
Last Updated on Sep 13, 2023
-
CEO & President of SK Bioscience Co Ltd.
Life Summary
Ahn Jae-yong is the CEO and President of SK Bioscience.
As sales related to COVID-19 vaccines decline, he is focusing on securing new growth drivers.
In preparation for the 'next pandemic,' he is exploring new fields such as messenger RNA (mRNA) vaccines and cell and gene therapy.
He was born on November 14, 1967, in Seoul.
He graduated from Yeouido High School in Seoul and studied economics at Yonsei University. He completed his Master of Business Administration (MBA) at the University of Chicago Booth School of Business.
After working at Korea Export Insurance Corporation, he moved to SK Chemicals.
At SK Chemicals, he served as the head of the strategy team and the head of strategic planning. He led the launch of the world's first quadrivalent cell-culture influenza vaccine, "SkyCellflu Quadrivalent," as the head of the vaccine business division.
When the vaccine business division of SK Chemicals spun off to become SK Bioscience, he was appointed as CEO and was promoted to president.
He emphasizes collaboration with overseas institutions for the growth of the vaccine business. He believes that for the company to grow, it is essential to create an environment where employees can work effectively.
#SKBioscience #AhnJaeyong #COVID19 #vaccines #mRNA #geneTherapy #businessLeadership #pandemicPreparation #globalCollaboration #employeeWellbeing
As sales related to COVID-19 vaccines decline, he is focusing on securing new growth drivers.
In preparation for the 'next pandemic,' he is exploring new fields such as messenger RNA (mRNA) vaccines and cell and gene therapy.
He was born on November 14, 1967, in Seoul.
He graduated from Yeouido High School in Seoul and studied economics at Yonsei University. He completed his Master of Business Administration (MBA) at the University of Chicago Booth School of Business.
After working at Korea Export Insurance Corporation, he moved to SK Chemicals.
At SK Chemicals, he served as the head of the strategy team and the head of strategic planning. He led the launch of the world's first quadrivalent cell-culture influenza vaccine, "SkyCellflu Quadrivalent," as the head of the vaccine business division.
When the vaccine business division of SK Chemicals spun off to become SK Bioscience, he was appointed as CEO and was promoted to president.
He emphasizes collaboration with overseas institutions for the growth of the vaccine business. He believes that for the company to grow, it is essential to create an environment where employees can work effectively.
#SKBioscience #AhnJaeyong #COVID19 #vaccines #mRNA #geneTherapy #businessLeadership #pandemicPreparation #globalCollaboration #employeeWellbeing